AU2018378078B2 - IL-2 muteins and uses thereof - Google Patents

IL-2 muteins and uses thereof Download PDF

Info

Publication number
AU2018378078B2
AU2018378078B2 AU2018378078A AU2018378078A AU2018378078B2 AU 2018378078 B2 AU2018378078 B2 AU 2018378078B2 AU 2018378078 A AU2018378078 A AU 2018378078A AU 2018378078 A AU2018378078 A AU 2018378078A AU 2018378078 B2 AU2018378078 B2 AU 2018378078B2
Authority
AU
Australia
Prior art keywords
leu
ser
lys
thr
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018378078A
Other languages
English (en)
Other versions
AU2018378078A1 (en
Inventor
Nathan HIGGINSON-SCOTT
Kevin Lewis Otipoby
Erik Robert Sampson
Joanne L. Viney
Jyothsna Visweswaraiah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pandion Operations Inc
Original Assignee
Pandion Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/109,897 external-priority patent/US10174092B1/en
Application filed by Pandion Operations Inc filed Critical Pandion Operations Inc
Publication of AU2018378078A1 publication Critical patent/AU2018378078A1/en
Assigned to Pandion Operations, Inc. reassignment Pandion Operations, Inc. Amend patent request/document other than specification (104) Assignors: Pandion Therapeutics, Inc.
Application granted granted Critical
Publication of AU2018378078B2 publication Critical patent/AU2018378078B2/en
Priority to AU2024216451A priority Critical patent/AU2024216451A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018378078A 2017-12-06 2018-11-28 IL-2 muteins and uses thereof Active AU2018378078B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024216451A AU2024216451A1 (en) 2017-12-06 2024-08-29 IL-2 muteins and uses thereof

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762595357P 2017-12-06 2017-12-06
US62/595,357 2017-12-06
US201862675972P 2018-05-24 2018-05-24
US62/675,972 2018-05-24
US201862721644P 2018-08-23 2018-08-23
US16/109,875 2018-08-23
US16/109,897 2018-08-23
US16/109,897 US10174092B1 (en) 2017-12-06 2018-08-23 IL-2 muteins
US16/109,875 US10174091B1 (en) 2017-12-06 2018-08-23 IL-2 muteins
US62/721,644 2018-08-23
PCT/US2018/062808 WO2019112854A1 (en) 2017-12-06 2018-11-28 Il-2 muteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024216451A Division AU2024216451A1 (en) 2017-12-06 2024-08-29 IL-2 muteins and uses thereof

Publications (2)

Publication Number Publication Date
AU2018378078A1 AU2018378078A1 (en) 2020-06-18
AU2018378078B2 true AU2018378078B2 (en) 2024-07-25

Family

ID=66751187

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018378078A Active AU2018378078B2 (en) 2017-12-06 2018-11-28 IL-2 muteins and uses thereof
AU2024216451A Pending AU2024216451A1 (en) 2017-12-06 2024-08-29 IL-2 muteins and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024216451A Pending AU2024216451A1 (en) 2017-12-06 2024-08-29 IL-2 muteins and uses thereof

Country Status (12)

Country Link
EP (1) EP3720470A4 (enExample)
JP (1) JP7250790B2 (enExample)
KR (3) KR102687035B1 (enExample)
CN (2) CN118515780A (enExample)
AU (2) AU2018378078B2 (enExample)
BR (1) BR112020011343A2 (enExample)
CA (1) CA3083941A1 (enExample)
IL (1) IL274844A (enExample)
MX (1) MX2020005208A (enExample)
SG (1) SG11202003965VA (enExample)
WO (1) WO2019112854A1 (enExample)
ZA (1) ZA202003386B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
WO2019112852A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Targeted immunotolerance
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
MX2022001061A (es) 2019-07-26 2022-02-14 Visterra Inc Agentes de interleuquina-2 y usos de los mismos.
BR112022003163A2 (pt) * 2019-08-19 2022-05-17 Pandion Operations Inc Imunotolerância alvejada com um agonista de pd-1
CN110642934B (zh) * 2019-09-10 2022-08-23 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
AU2020368447A1 (en) * 2019-10-15 2022-04-28 Modernatx, Inc. mRNA encoding immune modulating polypeptides and uses thereof
US20210188934A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CN112358540A (zh) * 2020-11-03 2021-02-12 安徽环球基因科技有限公司 一种重组il2在毕赤酵母中的生产方法
AU2021391924A1 (en) 2020-12-04 2023-06-22 The General Hospital Corporation Methods of using interleukin-2 agents
AU2023227283A1 (en) * 2022-03-03 2024-09-19 Hainan Simcere Pharmaceutical Co., Ltd. Pharmaceutical composition of il2 mutant-antibody fc block fusion protein and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140286898A1 (en) * 2013-03-14 2014-09-25 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1007907B (zh) * 1985-04-30 1990-05-09 弗·哈夫曼-拉罗彻有限公司 重组人类白细胞介素-2的提纯
US7569215B2 (en) * 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
CA2860170C (en) * 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
US20140170153A1 (en) * 2011-05-31 2014-06-19 Novo Nordisk A/S Il-21 epitope and il-21 ligands
DK3172227T3 (da) * 2014-07-21 2019-12-02 Delinia Inc Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme
CN115073581A (zh) * 2016-05-04 2022-09-20 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
WO2018184965A1 (en) * 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
WO2019112852A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Targeted immunotolerance
CN111010866A (zh) * 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
EP3876986A4 (en) * 2018-09-18 2022-06-01 Pandion Operations, Inc. Targeted immunotolerance

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140286898A1 (en) * 2013-03-14 2014-09-25 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells

Also Published As

Publication number Publication date
JP7250790B2 (ja) 2023-04-03
AU2018378078A1 (en) 2020-06-18
CA3083941A1 (en) 2019-06-13
SG11202003965VA (en) 2020-06-29
CN111432831B (zh) 2024-08-16
EP3720470A4 (en) 2021-09-15
AU2024216451A1 (en) 2024-09-26
KR102684426B1 (ko) 2024-07-11
CN118515780A (zh) 2024-08-20
WO2019112854A1 (en) 2019-06-13
KR20240115352A (ko) 2024-07-25
KR20200097275A (ko) 2020-08-18
BR112020011343A2 (pt) 2020-11-17
JP2021507690A (ja) 2021-02-25
EP3720470A1 (en) 2020-10-14
ZA202003386B (en) 2025-04-30
KR102687035B1 (ko) 2024-07-22
MX2020005208A (es) 2020-08-20
KR20240039201A (ko) 2024-03-26
IL274844A (en) 2020-07-30
CN111432831A (zh) 2020-07-17

Similar Documents

Publication Publication Date Title
US11965008B2 (en) IL-2 muteins and uses thereof
AU2018378078B2 (en) IL-2 muteins and uses thereof
US11779632B2 (en) IL-2 muteins and uses thereof
KR20110112299A (ko) 자가면역 및 염증성 장애의 치료에 사용하기 위한 가용성 폴리펩티드
AU2013223801B2 (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
KR20180050179A (ko) 변형된 pd-l1 단백질 및 이의 용도
USRE50550E1 (en) IL-2 muteins and uses thereof
CN116113428A (zh) 白细胞介素-2突变蛋白及其用途
EA042572B1 (ru) Мутеины il-2 и способы их применения
HK40034288A (en) Il-2 muteins and uses thereof
HK40034288B (zh) Il-2突变蛋白及其用途

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: PANDION OPERATIONS, INC.

Free format text: FORMER NAME(S): PANDION THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)